88%Confidence
0Views
FDASource
2026-03-02Date
Summary
Fresenius Kabi Compounding's recall for lack of sterility assurance in thiamine HCl compounded sterile preparations highlights systemic quality issues in its Fagron Sterile Services unit. This raises concerns about the reliability of its compounding operations and potential liability from patient infections.
Actionable: Evaluate Fresenius Kabi's compounding segment for recurring quality problems and consider the impact on its broader pharmaceutical services reputation.
AI Confidence: 88%
Data Points
firmFresenius Kabi Compounding, LLC
classificationClass II
statusOngoing
distributionUS Nationwide.
productthiamine HCl, 500 mg, 500 mg added to 100 mL, 0.9% Sodium Chloride Injection, USP, Fagron Sterile Services, 20 Dan Road, Canton, MA 02021, NDC 71506-0
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now